GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Cash From Discontinued Investing Activities

ProKidney (ProKidney) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

ProKidney's cash from discontinued investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means ProKidney received $0.00 Mil from discontinued investing activities. ProKidney's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


ProKidney Cash From Discontinued Investing Activities Historical Data

The historical data trend for ProKidney's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Cash From Discontinued Investing Activities Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
- - - -

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ProKidney Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProKidney Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of ProKidney's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (ProKidney) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Cash From Discontinued Investing Activities
Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Executives
Chamath Palihapitiya 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton officer: EVP, Clinical Development 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen 10 percent owner 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger officer: Chief People Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle director
Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

ProKidney (ProKidney) Headlines

From GuruFocus

ProKidney to Participate in Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 11-11-2022